Pathogenesis of Pulmonary Diseases
COPD is a slowly progressive condition characterized by airflow limitation, which is largely irreversible. It is characterized and defined by limitation of expiratory airflow. The current scenario is chronic airflow limitation results from an abnormal inflammatory response to inhaled particles and gases in the lung. The inflammatory mediators, including oxidants and proteases, are believed to play a major role in causing lung injury. Pathogenesis of COPD-an imbalance between proteases and antiproteases and an imbalance between oxidants and oxidative stress in the lungs. The pathological process of chronic lung disease is based on the concept that pulmonary diseases involve stages of commencement by pollutants, infectious agents and exposure to smoke, consolidation and progression. Tissue damage involves complex interactions among oxidative stress, chronic inflammation, extracellular matrix proteolysis, and apoptotic and autophagic cell death.
- Apoptosis
- Hyperinflation
- Inflammation
- Vasoconstriction
- Emphysema
Related Conference of Pathogenesis of Pulmonary Diseases
6th International Conference on Tuberculosis, Lung Health and Respiratory Diseases
16th International Conference on Pulmonary & Respiratory Medicine
18th International Conference on Chronic Obstructive Pulmonary Disease
Pathogenesis of Pulmonary Diseases Conference Speakers
Recommended Sessions
Related Journals
Are you interested in
- Advanced Lung Imaging - PULMONOLOGY 2026 (France)
- AI in Pulmonary Diagnostics - PULMONOLOGY 2026 (France)
- AI in Respiratory Care - COPD SUMMIT 2026 (Italy)
- Air Pollution & Tobacco Control - COPD SUMMIT 2026 (Italy)
- Asthma COPD Overlap (ACO) - COPD SUMMIT 2026 (Italy)
- Asthma: New Insights & Therapies - COPD SUMMIT 2026 (Italy)
- Bronchoscopy & Airway Techniques - COPD SUMMIT 2026 (Italy)
- Cardiopulmonary Disease - Tuberculosis-2026 (France)
- Chronic Obstructive Pulmonary Disease (COPD) - Tuberculosis-2026 (France)
- Climate Change and Respiratory Diseases - Tuberculosis-2026 (France)
- COPD & Cardiovascular Diseases - COPD SUMMIT 2026 (Italy)
- COPD Diagnosis & Guidelines - COPD SUMMIT 2026 (Italy)
- COPD Innovations - PULMONOLOGY 2026 (France)
- COPD Pathogenesis - COPD SUMMIT 2026 (Italy)
- COPD Pharmacotherapy - COPD SUMMIT 2026 (Italy)
- COPD Prevention & Self-Management - COPD SUMMIT 2026 (Italy)
- COPD: Advances & Management - COPD SUMMIT 2026 (Italy)
- Critical Care Pulmonology - PULMONOLOGY 2026 (France)
- Cystic Fibrosis - COPD SUMMIT 2026 (Italy)
- Digital Respiratory Health - PULMONOLOGY 2026 (France)
- Drug-Resistant Tuberculosis: - Tuberculosis-2026 (France)
- Early Detection and Diagnosis - Tuberculosis-2026 (France)
- Environmental Lung Diseases - PULMONOLOGY 2026 (France)
- Epidemiology of TB Disease - Tuberculosis-2026 (France)
- Gastroesophageal reflux disease (GERD) - Tuberculosis-2026 (France)
- Infection Control Measures - Tuberculosis-2026 (France)
- Integrated Healthcare Approach - Tuberculosis-2026 (France)
- Interstitial Lung Diseases - PULMONOLOGY 2026 (France)
- Interventional Pulmonology - PULMONOLOGY 2026 (France)
- Interventional Pulmonology - COPD SUMMIT 2026 (Italy)
- Latent TB Infection and Active TB Disease - Tuberculosis-2026 (France)
- Lung Cancer Biomarkers - PULMONOLOGY 2026 (France)
- Lung Cancer: Diagnosis & Treatment - COPD SUMMIT 2026 (Italy)
- Lung Cancer: Screening, Diagnosis & Treatment - Tuberculosis-2026 (France)
- Lung Fibrosis - COPD SUMMIT 2026 (Italy)
- Lung Function in Men with and without HIV - Tuberculosis-2026 (France)
- Lung Infection - Tuberculosis-2026 (France)
- Lung Transplantation - COPD SUMMIT 2026 (Italy)
- Mechanical Ventilation Strategies - PULMONOLOGY 2026 (France)
- Multidrug-resistant TB - Tuberculosis-2026 (France)
- Mycobacterial Infections - Tuberculosis-2026 (France)
- Next-Gen COPD Treatments - COPD SUMMIT 2026 (Italy)
- Non-Invasive Ventilation (NIV) - COPD SUMMIT 2026 (Italy)
- Nutrition and Tuberculosis - Tuberculosis-2026 (France)
- One Health Approach to TB Control - Tuberculosis-2026 (France)
- Palliative Care for Advanced Lung Cancer - Tuberculosis-2026 (France)
- Pediatric Pulmonology - PULMONOLOGY 2026 (France)
- Pediatric Respiratory Care - COPD SUMMIT 2026 (Italy)
- Pediatric Tuberculosis - Tuberculosis-2026 (France)
- Personalized Pulmonary Medicine - COPD SUMMIT 2026 (Italy)
- Pneumonia & Tuberculosis - COPD SUMMIT 2026 (Italy)
- Precision Respiratory Medicine - PULMONOLOGY 2026 (France)
- Preventive Therapy - Tuberculosis-2026 (France)
- Pulmonary Complications of Endocrine Diseases - Tuberculosis-2026 (France)
- Pulmonary Diseases and Therapeutics - Tuberculosis-2026 (France)
- Pulmonary Edema - Tuberculosis-2026 (France)
- Pulmonary Fibrosis Research - PULMONOLOGY 2026 (France)
- Pulmonary Hypertension - PULMONOLOGY 2026 (France)
- Pulmonary Hypertension - COPD SUMMIT 2026 (Italy)
- Pulmonary Rehabilitation - PULMONOLOGY 2026 (France)
- Pulmonary Rehabilitation - COPD SUMMIT 2026 (Italy)
- Research and Innovation - Tuberculosis-2026 (France)
- Respiratory Drug Delivery - PULMONOLOGY 2026 (France)
- Respiratory Infections - COPD SUMMIT 2026 (Italy)
- Respiratory Infections - PULMONOLOGY 2026 (France)
- Severe Asthma Therapies - PULMONOLOGY 2026 (France)
- Sleep & Breathing Disorders - PULMONOLOGY 2026 (France)
- Sleep Apnea - COPD SUMMIT 2026 (Italy)
- TB Clinical Trials - Tuberculosis-2026 (France)
- TB Vaccines - Tuberculosis-2026 (France)
- TB-HIV Co-Infection: - Tuberculosis-2026 (France)
- TB-HIV Co-infections - Tuberculosis-2026 (France)
- Thoracic Surgery Advances - PULMONOLOGY 2026 (France)
- Tuberculosis in Vulnerable Populations - Tuberculosis-2026 (France)
- Vaccination Programs: - Tuberculosis-2026 (France)
